Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended July 31, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File No. 001-36830 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 20-0915291 (State or other jurisd ...

Exhibit 99.1 KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results -EKTERLY® now approved in the US and UK; first and only oral on-demand therapy for acute attacks of hereditary angioedema- -Initiated US EKTERLY launch in July; received 460 patient start forms through August- -European Medicines Agency adopted a positive opinion recommending approval of sebetralstat and confirmed maintenance of orphan designation in EU; decision expected early October- -$191M in c ...

Group 1 - KalVista Pharmaceuticals is set to release its first-quarter earnings results on September 11, with analysts expecting a loss of $0.96 per share compared to a loss of $0.87 per share in the same quarter last year [1] - The company is projected to report quarterly revenue of $2.09 million [1] - On August 11, KalVista announced the maintenance of Orphan Designation for Sebetralstat in the European Union [2] Group 2 - KalVista Pharmaceuticals shares experienced a decline of 2.2%, closing at $15.61 [2] - Analysts have provided various ratings for KalVista, with HC Wainright & Co. maintaining a Buy rating and a price target of $27 [4] - JMP Securities increased its price target for KalVista from $19 to $27 while maintaining a Market Outperform rating [4]

Negative Earnings: Analysts predict an EPS of -$0.91 and revenue of approximately $2.1 million.Financial Challenges: Despite a P/E ratio of -4.32, challenges in generating positive cash flow are evident, with an enterprise value to operating cash flow ratio of -4.61.Strong Liquidity: KalVista maintains a current ratio of 5.35, indicating a strong liquidity position to cover short-term liabilities.KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is a biopharmaceutical company focused on developing small molecule ...

Company Overview - KalVista Pharmaceuticals is a newly commercial stage pharmaceuticals company [2] - The company has launched its drug EKTERLY for the treatment of acute attacks of hereditary angioedema, which was approved by the FDA in early July [2] Product Launch and Approvals - EKTERLY was launched immediately after FDA approval and the company closed its first fiscal quarter as a commercial entity on July 31 [2] - The drug has also received approval from the U.K. MHRA and is set to launch in the U.K. next year [3] - The CHMP in the EU recommended approval for EKTERLY at the end of July, with formal approval expected in October [3] - KalVista is pursuing approvals in four additional countries, indicating a strategy for global expansion [3]

Market Overview - U.S. stock futures are lower, with Dow futures down approximately 100 points on Monday [1] - Ultragenyx Pharmaceutical Inc. shares fell 8% to $27.15 after receiving a Complete Response Letter from the FDA for its gene therapy UX111 [1] Company-Specific Movements - MiNK Therapeutics, Inc. shares dropped 31% to $44.25 after a significant 730% increase on Friday due to a publication announcement [3] - Above Food Ingredients Inc. shares decreased 21.3% to $2.84 following a 134% rise on Friday after announcing a merger agreement [3] - Newegg Commerce, Inc. shares fell 11.3% to $43.66 after a 71% gain on Friday [3] - CEL-SCI Corporation shares declined 11% to $3.08 after an 8% drop on Friday, following a partnership announcement with a Saudi Arabian company [3] - Unusual Machines, Inc. shares slipped 8% to $11.13 after a 39% increase on Friday [3] - Gossamer Bio, Inc. shares fell 6.6% to $1.2700 after completing enrollment in a Phase 3 study for pulmonary arterial hypertension [3] - Gilat Satellite Networks Ltd. shares decreased 4.1% to $7.22 after announcing over $22 million in orders from satellite operators [3] - KalVista Pharmaceuticals, Inc. shares dipped 4% to $13.94 after reporting a wider-than-expected quarterly loss [3] - Apple Inc. shares fell 1% to $209.22 amid a significant management reshuffle, with CEO Tim Cook remaining in charge despite challenges [3]

Core Insights - KalVista Pharmaceuticals' shares have increased by 36% following the FDA's approval of its lead drug, sebetralstat, for hereditary angioedema (HAE) [1][6] - Sebetralstat, marketed as Ekterly, is the first oral on-demand therapy for HAE, marking a significant milestone for KalVista as it transitions into a commercial-stage biotech [2][6] Company Overview - Ekterly is designed for the treatment of acute HAE attacks in individuals aged 12 and older, providing a more convenient alternative to existing injectable treatments [2][5] - The approval of Ekterly allows KalVista to tap into a niche but lucrative market, potentially generating recurring revenue [2] Stock Performance - Year-to-date, KalVista's shares have surged by 89%, significantly outperforming the industry average growth of 5% [3] Treatment Paradigm Shift - Ekterly's oral formulation offers a game-changing advancement in HAE treatment, allowing for timely administration at the onset of symptoms, which is crucial for effective management [5][7] - The drug's safety profile is favorable compared to Takeda's Kalbitor, which has a boxed warning for anaphylaxis, potentially influencing prescribing decisions [8][9] Clinical Data - The FDA approval was supported by data from the KONFIDENT study, which demonstrated that Ekterly provided faster symptom relief and reduced attack severity compared to placebo [9] - KalVista is also conducting a phase III study, KONFIDENT-KID, to evaluate Ekterly in pediatric patients aged 2-11, with results expected later this year [10]

[Operational Update and Business Highlights](index=1&type=section&id=Recent%20Business%20Highlights) KalVista achieved FDA approval for EKTERLY® (sebetralstat) for HAE, initiating U.S. launch and global expansion efforts - Received FDA approval for **EKTERLY® (sebetralstat)**, the first and only oral on-demand treatment for hereditary angioedema (HAE) in patients 12 years and older[1](index=1&type=chunk)[3](index=3&type=chunk) - Entered into exclusive licensing agreements to commercialize sebetralstat in **Japan with Kaken Pharmaceutical** and in **Canada with Pendopharm**[1](index=1&type=chunk)[6](index=6&type=chunk) - Six additional global regulatory submissions for EKTERLY® are currently under review[1](index=1&type=chunk) - Presented new positive clinical data at EAACI, C1-INH, and EAC conferences, highlighting EKTERLY's **rapid relief**, efficacy with long-term prophylaxis (LTP), and utility in treating severe attacks[3](index=3&type=chunk)[6](index=6&type=chunk) [Fiscal Year 2025 Financial Results](index=2&type=section&id=Financial%20Results%20for%20Fiscal%20Year%20Ended%20April%2030%2C%202025%3A) KalVista's FY2025 net loss rose to $183.4M due to increased G&A, offset by strong $220.6M cash - Cash, cash equivalents, and marketable securities were **$220.6 million** as of April 30, 2025, which is expected to provide a financial runway into 2027[1](index=1&type=chunk)[6](index=6&type=chunk) Expense Category Analysis | Expense Category | FY 2025 | FY 2024 | Change Driver | | :--- | :--- | :--- | :--- | | Research & Development | $71.7M | $86.2M | Decrease due to reduced clinical trial and preclinical expenses | | General & Administrative | $116.3M | $54.3M | Increase primarily due to pre-commercial planning for EKTERLY | [Consolidated Statements of Operations](index=5&type=section&id=Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Consolidated Statements of Operations Summary | Metric | FY 2025 (in thousands) | FY 2024 (in thousands) | | :--- | :--- | :--- | | Total operating expenses | $187,995 | $140,445 | | Operating loss | $(187,995) | $(140,445) | | Net loss | $(183,444) | $(126,644) | | Net loss per share | $(3.69) | $(3.44) | [Consolidated Balance Sheets](index=4&type=section&id=Consolidated%20Balance%20Sheets) Consolidated Balance Sheets Summary | Metric | April 30, 2025 (in thousands) | April 30, 2024 (in thousands) | | :--- | :--- | :--- | | Cash, cash equivalents & Marketable securities | $220,617 | $210,401 | | Total Assets | $250,770 | $235,404 | | Total Liabilities | $155,379 | $28,822 | | Stockholders' Equity | $95,391 | $206,582 |

Core Insights - KalVista Pharmaceuticals, Inc. received FDA approval for its oral on-demand Hereditary Angioedema plasma kallikrein inhibitor drug EKTERLY (sebetralstat) on July 7, 2025, marking a significant milestone for the company [2]. Company Overview - KalVista Pharmaceuticals is focused on developing treatments for hereditary angioedema, a rare genetic condition that causes severe swelling [2]. Market Context - The approval of EKTERLY positions KalVista favorably within the biotech sector, particularly in the niche market of hereditary angioedema treatments, which may enhance its competitive edge [2].